Does Anthem (Elevance Health) Cover Reclast (Zoledronic Acid)?

Anthem's Coverage Policy for Reclast

Anthem (Elevance Health) classifies Reclast (zoledronic acid 5 mg IV) as a covered medical benefit for the treatment of osteoporosis and Paget's disease of bone on its commercial PPO and HMO plans. Coverage is not automatic. The plan requires prior authorization (PA) and, in most cases, documented step therapy before approving the infusion.

Anthem's clinical policy bulletins reference FDA-approved indications, which include treatment and prevention of postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, osteoporosis in men, and Paget's disease [1]. The FDA-approved prescribing information specifies a single 5 mg intravenous infusion given once every 12 months for osteoporosis treatment, or once every 24 months for prevention. Because the drug is administered by IV infusion in a clinic or infusion center, Anthem processes it under the medical benefit rather than the pharmacy benefit on most plans, which changes how cost-sharing applies.

Anthem Medicaid managed-care plans and Medicare Advantage plans may follow different formulary and PA rules. Always verify coverage through the member portal or by calling the number on the back of the insurance card.

Formulary Tier and Cost-Sharing

On most Anthem commercial formularies, zoledronic acid sits on a specialty tier (Tier 4 or Tier 5). That placement matters because specialty-tier drugs carry higher cost-sharing than preferred generics or brand-name medications on lower tiers.

The manufacturer list price for a single Reclast infusion is approximately $1,500 [2]. Cash-pay pricing at outpatient infusion centers averages around $600 when purchased without insurance, though prices vary by region and facility. With Anthem approval, members typically pay a specialty copay between $100 and $350 per infusion, or a coinsurance percentage (often 20% to 30%) after meeting the plan deductible. High-deductible health plans paired with an HSA may require the full negotiated rate until the deductible is satisfied.

Generic zoledronic acid 5 mg/100 mL IV solution is available and is often significantly cheaper than the brand-name Reclast. Some Anthem plans preferentially cover the generic formulation at a lower tier. Ask the prescribing physician to write the prescription for "zoledronic acid" rather than "Reclast" to allow generic substitution at the pharmacy or infusion center, which can reduce copay obligations.

Prior Authorization Requirements

Anthem rates as "moderate" in PA difficulty for Reclast relative to other specialty osteoporosis drugs. The PA process confirms that the drug is medically necessary and that the member meets clinical criteria.

Typical documentation Anthem requires for PA approval includes:

• A confirmed diagnosis of osteoporosis (DXA T-score of <-2.5 at the spine, femoral neck, or total hip) or osteopenia with a high FRAX fracture-risk score, or a history of fragility fracture [3]
• Documentation that the patient has tried and failed, or has a documented contraindication to, at least one oral bisphosphonate (alendronate or risedronate)
• Baseline labs including serum calcium, 25-hydroxyvitamin D, and estimated GFR (zoledronic acid is contraindicated when creatinine clearance is <35 mL/min) [1]
• A completed Anthem PA request form submitted by the prescribing provider

Turnaround for standard PA requests is typically 5 to 15 business days. Urgent requests can be processed within 72 hours. If the infusion is scheduled at a hospital outpatient department, the facility may also need to obtain a separate pre-service authorization.

Step Therapy: What Anthem Expects You to Try First

Step therapy is one of the most common obstacles to Reclast approval on Anthem plans. The insurer's step-therapy protocol generally requires a trial of an oral bisphosphonate before authorizing IV zoledronic acid.

In practice, that means your prescriber must document that you took alendronate (Fosamax) or risedronate (Actonel) for a minimum period (often 90 days) and either experienced intolerable side effects, had a contraindication to oral therapy, or showed inadequate response. The rationale is cost containment: generic alendronate costs $4 to $20 per month, while a single Reclast infusion runs roughly 50 to 375 times that monthly cost depending on copay structure.

Conditions that commonly qualify for a step-therapy override include:

• Esophageal stricture, Barrett's esophagus, or active esophageal ulcer (oral bisphosphonates are contraindicated) [4]
• Documented GI intolerance to oral bisphosphonates (severe esophagitis, persistent nausea, or inability to remain upright for 30 to 60 minutes after dosing)
• Cognitive impairment or physical disability preventing the patient from following oral bisphosphonate dosing instructions
• Non-adherence risk identified by the prescribing physician, particularly for patients with demonstrated poor compliance with weekly or monthly oral regimens
• A new vertebral or hip fracture occurring during oral bisphosphonate therapy, indicating treatment failure

The landmark HORIZON-PFT trial (N=7,765) demonstrated that once-yearly IV zoledronic acid 5 mg reduced vertebral fractures by 70%, hip fractures by 41%, and non-vertebral fractures by 25% over three years compared to placebo [5]. Citing this trial data in the PA or step-therapy exception request strengthens the clinical case, especially for patients at high fracture risk.

How Zoledronic Acid Compares to Other Covered Options

Understanding where Reclast sits in Anthem's osteoporosis treatment hierarchy helps frame what the insurer will approve first and what it considers second-line.

Oral bisphosphonates (Tier 1, preferred generic). Alendronate 70 mg weekly and risedronate 35 mg weekly are the default first-line agents. Copays are minimal. Anthem almost always requires a trial of one of these before covering IV options.

Denosumab (Prolia). This subcutaneous injection given every 6 months is also classified as specialty tier on most Anthem formularies. PA is required, and step therapy with an oral bisphosphonate is typically expected. Denosumab carries a unique concern: discontinuation leads to rapid bone loss and increased vertebral fracture risk within 12 to 18 months [6]. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68% over 3 years [7]. Anthem may approve either denosumab or zoledronic acid after oral bisphosphonate failure.

Romosozumab (Evenity). This bone-forming agent is reserved for severe osteoporosis and carries the highest PA burden. Anthem restricts romosozumab to patients with very high fracture risk and generally requires documentation of prior treatment failure. The ARCH trial (N=4,093) demonstrated superiority over alendronate in reducing new vertebral and clinical fractures, but the drug carries a cardiovascular warning [8].

Teriparatide (Forteo) and abaloparatide (Tymlos). These parathyroid hormone analogs are another step up in the treatment algorithm. They are typically approved for severe osteoporosis after bisphosphonate failure.

For most Anthem members with osteoporosis who cannot tolerate oral bisphosphonates, zoledronic acid represents a well-supported second-line choice with strong efficacy data and the convenience of once-yearly dosing.

How to Appeal a Denied Reclast Claim

If Anthem denies your Reclast PA request, the denial letter will include the specific reason and instructions for appeal. The two-stage appeal process works as follows.

Internal appeal (Level 1). You or your prescriber submits a written appeal to Anthem within 180 days of the denial notice. Include supporting clinical documentation: DXA scan results, FRAX score, records of oral bisphosphonate trial and failure, relevant lab work, and a letter of medical necessity from the prescribing physician. The physician's letter should cite guideline recommendations from the American Association of Clinical Endocrinology (AACE) and the Endocrine Society, which support IV bisphosphonate use in patients who cannot tolerate oral therapy [9]. Reference to the HORIZON-PFT trial data is appropriate here. Anthem must respond to a standard appeal within 30 days, or within 72 hours for an expedited (urgent) appeal.

External review (Level 2). If the internal appeal is denied, you have the right to request an independent review by a state-designated Independent Review Organization (IRO). The IRO assigns the case to a board-certified physician who was not involved in the original denial. State insurance departments regulate the external review process, and the IRO's decision is binding on Anthem in most states.

Tips that improve appeal success:

• Submit a peer-to-peer review request. Your prescriber can speak directly with Anthem's medical director, often resolving denials faster than written appeals.
• Document everything. GI symptoms from oral bisphosphonates should appear in office visit notes before the PA request, not only in the appeal letter.
• Include guideline citations. The AACE/ACE 2020 clinical practice guidelines explicitly recommend IV zoledronic acid for patients intolerant of or non-adherent to oral bisphosphonates [9].
• Use CPT and ICD-10 codes accurately. Zoledronic acid infusion for osteoporosis uses CPT 96413 (chemotherapy administration, IV infusion) and HCPCS J3489 (zoledronic acid 1 mg). Incorrect coding is a frequent cause of claim denials that is easily corrected on appeal.

Manufacturer Savings and Patient Assistance Programs

Novartis, the manufacturer of brand-name Reclast, has offered copay assistance programs for eligible commercially insured patients. These programs may reduce out-of-pocket costs to as low as $0 to $25 per infusion for qualifying patients. Manufacturer savings cards generally cannot be combined with government insurance (Medicare, Medicaid, Tricare, or VA benefits) due to federal anti-kickback regulations.

For uninsured or underinsured patients, Novartis Patient Assistance Foundation (NPAF) offers free drug programs based on income eligibility. Patients with household incomes at or below 500% of the federal poverty level may qualify. Generic zoledronic acid manufacturers may offer their own patient assistance programs as well.

Check the Anthem plan's accumulator or maximizer policy before relying on a copay card. Some Anthem plans use copay accumulator adjustment programs that prevent manufacturer copay assistance from counting toward the annual deductible or out-of-pocket maximum [10]. Under these programs, when the copay card funding runs out, the member is responsible for the full cost-sharing amount as if no assistance had been applied. This policy varies by state and plan type.

Timing the Infusion for Maximum Insurance Benefit

Because zoledronic acid is dosed once yearly, timing the infusion strategically within the plan year can reduce overall costs. If your annual deductible resets on January 1, scheduling the infusion later in the year (after the deductible has been met through other medical expenses) means the plan covers a larger share of the infusion cost.

For patients on calendar-year high-deductible plans, pairing the infusion with other planned medical services in the same benefit year helps concentrate spending. One infusion per year also means that if Anthem's formulary or PA requirements change at plan renewal, you only need to manage the process once every 12 months.

Confirm that your infusion site is an in-network provider. IV bisphosphonate infusions administered at out-of-network facilities can result in balance billing and significantly higher patient responsibility, even with an approved PA.

Special Populations and Coverage Considerations

Medicare Advantage through Anthem. Anthem Medicare Advantage plans typically cover zoledronic acid under Part B (medical benefit) when administered in a physician's office or outpatient setting. Part B coverage for osteoporosis drugs applies specifically to injectable or infusible agents. The standard 20% Part B coinsurance applies after the deductible, and Medigap or supplemental plans may cover the remainder.

Glucocorticoid-induced osteoporosis. Patients on chronic corticosteroids (prednisone ≥7.5 mg/day for ≥3 months) represent a distinct population. The ACR 2022 guideline recommends bisphosphonate therapy for these patients regardless of fracture history when the FRAX score exceeds treatment thresholds [11]. PA requests citing glucocorticoid-induced osteoporosis often receive approval more readily because the indication is well-defined and the fracture risk is clearly elevated.

Male osteoporosis. Zoledronic acid is FDA-approved for increasing bone mass in men with osteoporosis. Anthem covers the drug for this indication under the same PA and step-therapy requirements. The HORIZON trial included a male-specific cohort demonstrating significant BMD increases at the lumbar spine and femoral neck in men treated with annual zoledronic acid [12].

Post-hip-fracture patients. The HORIZON-RFT trial (N=2,127) demonstrated that annual zoledronic acid given within 90 days of hip fracture repair reduced the risk of new clinical fractures by 35% and all-cause mortality by 28% [13]. This remains one of the only osteoporosis trials to show a mortality benefit. For Anthem members hospitalized for hip fracture, citing HORIZON-RFT data supports a strong case for PA approval without step therapy, given the urgency of secondary fracture prevention.